Table 1.
Bepipred 2.0 positive predictions (scoring > 0.5) for linear neutralizing epitopes covering targeted RBD and cleavage segments of the spike glycoprotein with targeted SARS-CoV-2 variants.
| Short Peptide Names | Neutralizing Epitope Sequence | Location | SARS-CoV-2 Variants | IFNepitope Score |
|---|---|---|---|---|
| A | QTGKIADYNYK | RBDg * | Wuhan_Reference B.1.1.7, A.23.1 B.1.525, B.1.617.2 |
0.23869643 |
| B | TEIYQAGSTPCNGVEG | RBDp * | Wuhan_Reference B.1.1.7, A.23.1 |
0.256374 |
| C | LQSYGFQPT | RBDp * | Wuhan_Reference P.1, B.1.351, B.1.1.7 A.23.1, B.1.525, B.1.617.2 |
0.25635466 |
| D | IRGDEVRQIAPGQTGKIADYNYKLPD | RBDg * | Wuhan_Reference B.1.1.7, A.23.1, B.1.525, B.1.617.2 |
0.22687041 |
| E | FSQILPDPSKPSKRS | TMPRSS-2 Cleavage site in S2 * | Wuhan_Reference P.1, B.1.351, B.1.1.7 A.23.1, B.1.525, B.1.617.2 |
3.6814886 |
| F | PFAMQMAYRFNG | S2 fragment | Wuhan_Reference P.1, B.1.351, B.1.1.7 A.23.1, B.1.525, B.1.617.2 |
3.5004815 |
* RBDg; spike amino acids (aa) sites 397–437, RBDp; aa 455–502 and S2; spike fragment 2.